The estimated Net Worth of Deborah Di Sanzo Eldracher is at least $4.1 Million dollars as of 17 October 2022. Ms. Eldracher owns over 28 units of Novanta Inc stock worth over $3,575,804 and over the last 9 years she sold NOVT stock worth over $404,094. In addition, she makes $121,402 as Independent Director at Novanta Inc.
Sign up
Ms. Eldracher NOVT stock SEC Form 4 insiders trading
Deborah has made over 8 trades of the Novanta Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 28 units of NOVT stock worth $1,808 on 17 October 2022.
The largest trade she's ever made was selling 1,834 units of Novanta Inc stock on 21 September 2022 worth over $131,278. On average, Deborah trades about 362 units every 52 days since 2016. As of 17 October 2022 she still owns at least 21,412 units of Novanta Inc stock.
You can see the complete history of Ms. Eldracher stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Deborah Eldracher biography
Deborah DiSanzo serves as Independent Director of the Company. Ms. DiSanzo has been a Director of the Company since May 9, 2019. Ms. DiSanzo has served as a Harvard University Advanced Leadership Initiative Fellow since December 2018. From September 2015 to December 2018, Ms. DiSanzo served as General Manager of IBM Watson Health at International Business Machines Corporation (“IBM”), the IBM business unit dedicated to health and healthcare analytics and artificial intelligence. From 2001 to December 2014, Ms. DiSanzo held various roles at Koninklijke Philips N.V. (“Philips”), a technology company, most recently as Chief Executive Officer of the Philips’ Healthcare division (“Philips Healthcare”) from April 2012 to December 2014 and prior to that as Executive Vice President over several business units within Philips Healthcare. Prior to Philips Healthcare, Ms. DiSanzo held senior roles at Heartstream, Incorporated (now part of Philips Healthcare), a medical device company, and Hewlett-Packard Company, an information technology company. Ms. DiSanzo currently serves on the Board of Directors of AstraZeneca PLC where she is a member of the Audit Committee and previously served on the Board of Directors of ReWalk Robotics Ltd. from 2015 to 2018. Ms. DiSanzo also serves on the Board of Directors of Project Hope where she is a member of the Audit Committee. Ms. DiSanzo has a Bachelor of Science degree from Merrimack College and an MBA from Babson College. As a senior executive in the healthcare industry for more than 25 years, Ms. DiSanzo brings significant leadership, operational and healthcare industry experience that is valuable to the Board as the Company continues to execute its plan to increase sales to medical end markets. Ms. DiSanzo’s presence on the Board also enhances the Board’s gender diversity.
What is the salary of Deborah Eldracher?
As the Independent Director of Novanta Inc, the total compensation of Deborah Eldracher at Novanta Inc is $121,402. There are 11 executives at Novanta Inc getting paid more, with Matthijs Glastra having the highest compensation of $4,058,920.
How old is Deborah Eldracher?
Deborah Eldracher is 60, she's been the Independent Director of Novanta Inc since 2019. There are 2 older and 10 younger executives at Novanta Inc. The oldest executive at Novanta Inc is Stephen Bershad, 78, who is the Independent Chairman of the Board.
What's Deborah Eldracher's mailing address?
Deborah's mailing address filed with the SEC is 7601, Penn Avenue South, Richfield, Hennepin County, Minnesota, 55423, United States.
Insiders trading at Novanta Inc
Over the last 8 years, insiders at Novanta Inc have traded over $115,059,741 worth of Novanta Inc stock. The most active insiders traders include Stephen W Bershad, Ira J Lamel, and Matthijs Glastra. On average, Novanta Inc executives and independent directors trade stock every 15 days with the average trade being worth of $1,701,396. The most recent stock trade was executed by Robert Buckley on 3 September 2024, trading 4,379 units of NOVT stock currently worth $61,875.
What does Novanta Inc do?
novanta (nasdaq: novt) delivers innovations that matter for its medical and advanced industrial oem customers. if you have a passion for solving complex technical problems that lead to breakthrough performance and that enhance people's lives, come join our growing team. here is a sample of the many exciting applications we serve: • innovations that ensure the safety of patients and efficient workflows in hospitals using our novel rfid technology • innovations in additive manufacturing, also known as 3-d metal printing, using our lightning fast lasers and laser beam steering sub-systems • innovations in minimally invasive surgery using our highly reliable insufflators, pumps and visualization systems • innovations in robotics and automation using our precision motors, encoders and drives for superior accuracy • innovations in smartphone production using our fast, accurate lasers and laser beam steering equipment along with our precision motion systems the driving force behind our grow
What does Novanta Inc's logo look like?
Complete history of Ms. Eldracher stock trades at Novanta Inc, Rewalk Robotics Ltd, and Best Buy Co
Novanta Inc executives and stock owners
Novanta Inc executives and other stock owners filed with the SEC include:
-
Matthijs Glastra,
Chief Executive Officer, Director -
Robert Buckley,
Chief Financial Officer -
Matthijs Glastra,
CEO & Chairman -
Brian Young,
Chief Human Resource Officer -
Robert J. Buckley,
Chief Financial Officer -
Brian S. Young,
Chief HR Officer -
Stephen Bershad,
Independent Chairman of the Board -
Ira Lamel,
Independent Director -
Thomas Secor,
Independent Director -
Brian King,
Independent Director -
Lonny Carpenter,
Independent Director -
Deborah Eldracher,
Independent Director -
Ray Nash,
Corp. Fin. Leader -
Heinrich Dreyer,
Group Pres of Vision -
Charlie Webster,
Exec. VP of Novanta Growth System & Global Supply Chain -
Kitty Sahin,
Exec. VP of Strategy & Bus. Devel. -
Sarah Betadam,
Chief Information Officer -
Peter L. Chang,
Corp. Controller & Chief Accounting Officer -
Harry L Bosco,
Director -
John A Roush,
Chief Executive Officer -
Dominic A Romeo,
Director -
Dennis J Fortino,
Director -
Peter L Chang,
CAO-Corporate Controller -
Frank Anders Wilson,
Director -
Darlene J. S. Solomon,
Director -
Mary Kay Ladone,
Director -
Maxine Lum Mauricio,
Director -
Katherine Ann Owen,
Director -
Robert Matthew Johnson,
Director -
Barbara B. Hulit,
Director -
Michele Davis Welsh,
General Counsel